Adherence with regulatory resolutions on prevention of NSAIDs-related gastrointestinal injury in Italy

International Journal of Clinical Pharmacy

Volumn 38, Issue 4, 2016, Pages 829-837

  Montagnani, Sabrina ^a   Tuccori, Marco ^b,c   Testi, Arianna ^d   Cristofano, Michele ^b   Corona, Tiberio ^d   Salvadori, Stefano ^e   Scarpignato, Carmelo ^f   Blandizzi, Corrado ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Tuscan Regional Centre of Pharmacovigilance   (Italy)

^d Pisa Health Authority   (Italy)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

Gastrointestinal injury; Italy; Misoprostol; Prescription data; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL DISCHARGE; HUMAN; ITALY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH PROTECTION; CHEMICALLY INDUCED; DRUG UTILIZATION; GASTROINTESTINAL DISEASES; MIDDLE AGED; PROTOCOL COMPLIANCE; TIME FACTOR; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL DISEASES; GUIDELINE ADHERENCE; HUMANS; ITALY; MALE; MIDDLE AGED; MISOPROSTOL; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84961807543     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-016-0291-8     Document Type: Article

References (33)

1. Adebajo A. Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care. BMC Fam Pract. 2012;13:23.
2. Scarpignato C, Hunt RH. Non-steroidal anti-inflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin N Am. 2010;39(3):433–64.
3. Straube S, Tramer MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41.
4. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033–8.
5. Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging. 2007;24(2):121–31.
6. Lanas A, Garcia Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2-inhibitors, traditional non-aspirin, non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8.
7. Rostom A, Wells G, Tugwell P, et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol. 2000;27(9):2203–14.
8. Moore RA, Derry S, Simon LS, Emery P. Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract. 2014;14(4):378–95.
9. Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21(1):3–8.
10. Chan FK, Graham DY. Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19(10):1051–61.
11. Scott SA, OwusuObeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175–89.
12. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810–23.
13. Charlot M, et al. Proton pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–86.
14. Scheiman JM. Prevention of NSAID-Induced Ulcers. Curr Treat Options Gastroenterol. 2008;11(2):125–34.
15. Graham DY, Agrawal NM, Campbell DR, NSAID-Associated Gastric Ulcer Prevention Study Group, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. Arch Intern Med. 2002;162(2):169–75.
16. 2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18(11–12):1137–47.
17. Hunt RH, Barkun AN, Baron D, et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol. 2002;16(4):231–40.
18. AIFA. Determinazione AIFA, 11 febbraio 2008—www.agenziafarmaco.gov.it. 2008. Last accessed 01 Sept 2015.
19. Reid M, Keniston A, Heller JC, et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421–5.
20. Murthy SK, Kauldher S, Targownik LE. Physicians’ approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 2006;23(9):1365–72.
21. Morini S, Zullo A, Oliveti D, et al. A very high rate of inappropriate use of gastroprotection for non steroidal anti-inflammatory drug therapy in primary care: a cross-sectional study. J Clin Gastroenterol. 2011;45(9):780–4.
22. Helsper CW, Smeets HM, Numans ME, et al. Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs. Pharmacoepidemiol Drug Saf. 2009;18(9):800–6.
23. Van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26(2):265–75.
24. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103(2):323–32.
25. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205–10.
26. World Health Organization. International classification of disease: injuries and causes of death. Ninth Revision (ICD-9). Geneva: World Health Organization; 1987.
27. AIFA. Determinazione AIFA, 22 settembre 2009—www.agenziafarmaco.gov.it. 2009. Last accessed 01 Sept 2015.
28. Scarpignato C, Pelosini I. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol. 1999;31(Suppl 1):S63–72.
29. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ. 1997;315(7119):1333–7.
30. Graham DY. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter. 2002;7(1):1–8.
31. Lanas A. Advances in gastrointestinal disorders associated with non-steroidal antiinflammatory agents and aspirin. Gastroenterol Hepatol. 2011;34(Suppl 2):36–42.
32. Ntaios G, Chatzinnikolaou A, Kaiafa G. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med. 2009;20(2):171–3.
33. OsMed working group. The use of drugs in Italy. National Report 2010. Rome: Il Pensiero Scientifico Editore. www.agenziafarmaco.gov.it/it/content/osmed-report. Last accessed 01 Sept 2015.